Darbitop 25mcg Injection
Marketer
Alniche Life Sciences Pvt Ltd
Salt Composition
Darbepoetin alfa (25mcg)
Overview Darbitop 25mcg Injection
Erythropoietin alfa (25 mcg injection) is indicated for treating anemia resulting from chronic kidney disease or chemotherapy. Its mechanism involves bone marrow stimulation to increase red blood cell production. Administered under strict medical supervision, this medication carries a risk of significant adverse reactions, mandating treatment by a qualified hematologist. Precise adherence to the physician's instructions is crucial. Commonly reported side effects include abdominal discomfort, hypertension, skin eruptions, injection site pain, dyspnea, cough, and peripheral swelling. Report symptoms of severe hypertension, such as intense headache, visual disturbances, nausea, vomiting, or convulsions, immediately. Regular blood tests to monitor electrolyte levels (potassium), hemoglobin, and blood cell counts are essential. Discontinue use and seek medical advice if experiencing shortness of breath or a skin rash. Prior to treatment, disclose any history of cardiac disease, hypertension, seizures, or stroke. Consult your physician regarding the medication's safety during pregnancy, breastfeeding, or pregnancy planning.
Uses of Darbitop 25mcg Injection
Managing anemia associated with chronic kidney failure | Addressing anemia resulting from cancer treatment with chemotherapy
Major Benefits of Darbitop 25mcg Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
Common Side effects of Darbitop 25mcg Injection:
- Abdominal pain
- High blood pressure
- Rash
- Injection site pain
- Breathlessness
- Cough
- Peripheral edema
- Procedural hypotension (low blood pressure)
- Convulsion
- Thromboembolism
How to use Darbitop 25mcg Injection:
This medication will be administered by your healthcare provider; self-medication is strictly prohibited.
How Darbitop 25mcg Injection works:
Darbepoetin alfa 25 mcg injection is a medication that boosts red blood cell production. This erythropoiesis-stimulating agent (ESA) acts by prompting the bone marrow to increase its output of red blood cells.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
The interaction of alcohol with Darbitop 25mcg Injection is undetermined. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Use of Darbitop 25mcg Injection during pregnancy may pose risks. While human research is scant, animal studies indicate potential harm to the fetus. A physician will assess the potential benefits against any risks prior to prescription. Consult your doctor for advice.
Breast feedingCONSULT YOUR DOCTOR
Administering Darbitop 25mcg Injection while breastfeeding may pose a risk. Available evidence from human studies indicates potential transfer to breast milk, potentially harming the infant.
DrivingSAFE
Administration of Darbitop 25mcg Injection typically does not impair driving ability.
KidneySAFE IF PRESCRIBED
Darbitop 25 mcg injection poses no safety concerns for patients with renal impairment; dosage modification is unnecessary.
LiverCAUTION
Individuals with hepatic impairment should exercise caution when using Darbitop 25mcg Injection. Dosage modification may be necessary. Physician consultation is recommended.
What if you forget to take Darbitop 25mcg Injection :
Should you forget a Darbitop 25mcg Injection, administer it immediately. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Darbitop 25mcg Injection
| Label | Value |
|---|---|
| Chemical Type | Amino Acid and Peptide Analogs |
| Developing Habits | No. |
| Treatment Category | KINSHIP |
| Actions | Erythropoietin-stimulating drug |
3,018 People bought this recently